Teva Announces Positive Long-Term SOLARIS Data for Investigational Once-Monthly Olanzapine LAI TEV-'749 in Schizophrenia
Teva Pharmaceuticals presented positive long-term data from the SOLARIS Phase 3 trial for its investigational once-monthly olanzapine LAI (TEV-'749) for schizophrenia. Over 50% of participants achieved stabilization, 21% met remission criteria, and few relapsed. The data also support switching from daily oral olanzapine to TEV-'749. Teva anticipates an FDA decision in Q4 2026.
How this was made
The 30-second read
Why it matters
The disclosed stabilization and remission rates suggest a differentiated product that could capture market share from oral olanzapine.
Market read
First public release of pivotal trial data for TEV‑'749, potentially influencing TEVA stock ahead of regulatory review.
What to watch
Regulatory timelines and competitive LAI products could moderate any short‑term rally.
Background
Teva is a major generic and specialty pharma firm; TEV‑'749 is its first subcutaneous olanzapine LAI candidate.
Ticker impact
Teva presented new post‑hoc Phase 3 SOLARIS data for its investigational olanzapine LAI TEV‑'749, showing >50% stabilization and low relapse rates.
moderate upside if data spurs expectations of approval
Data are first disclosed; large pharma with US listing; trial results are material for regulatory outcome.
Market effects
May lift sentiment for schizophrenia therapeutics and LAI antipsychotic pipeline companies.
Potentially supportive for US and EU biotech/pharma markets awaiting FDA/EMA decisions.
Adds optimism to global mental‑health drug development landscape.
Counterpoint
If FDA raises concerns, the data could be dismissed, limiting price impact.
Key entities
- CompanyTeva Pharmaceuticals
U.S. affiliate of Teva Pharmaceutical Industries Ltd.
- ExecutiveEric Hughes, MD, PhD
Executive Vice President, Global R&D and Chief Medical Officer at Teva.
